BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31505764)

  • 1. Twist1 Inactivation in Dmp1-Expressing Cells Increases Bone Mass but Does Not Affect the Anabolic Response to Sclerostin Neutralization.
    Lewis KJ; Choi RB; Pemberton EZ; Bullock WA; Firulli AB; Robling AG
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31505764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Gsα in osteocytes leads to osteopenia due to sclerostin induced suppression of osteoblast activity.
    Fulzele K; Dedic C; Lai F; Bouxsein M; Lotinun S; Baron R; Divieti Pajevic P
    Bone; 2018 Dec; 117():138-148. PubMed ID: 30266511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
    Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development.
    Yee CS; Manilay JO; Chang JC; Hum NR; Murugesh DK; Bajwa J; Mendez ME; Economides AE; Horan DJ; Robling AG; Loots GG
    J Bone Miner Res; 2018 Oct; 33(10):1748-1759. PubMed ID: 29750826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
    Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
    Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postnatal β-catenin deletion from Dmp1-expressing osteocytes/osteoblasts reduces structural adaptation to loading, but not periosteal load-induced bone formation.
    Kang KS; Hong JM; Robling AG
    Bone; 2016 Jul; 88():138-145. PubMed ID: 27143110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of the auxiliary α2δ1 voltage sensitive calcium channel subunit in osteocytes and late-stage osteoblasts impairs femur strength and load-induced bone formation in male mice.
    Wright CS; Lewis KJ; Semon K; Yi X; Reyes Fernandez PC; Rust K; Prideaux M; Schneider A; Pederson M; Deosthale P; Plotkin LI; Hum JM; Sankar U; Farach-Carson MC; Robling AG; Thompson WR
    J Bone Miner Res; 2024 Apr; 39(3):298-314. PubMed ID: 38477790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteocyte- and late osteoblast-derived NOTUM reduces cortical bone mass in mice.
    Nilsson KH; Henning P; El Shahawy M; Wu J; Koskela A; Tuukkanen J; Perret C; Lerner UH; Ohlsson C; Movérare-Skrtic S
    Am J Physiol Endocrinol Metab; 2021 May; 320(5):E967-E975. PubMed ID: 33749332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal changes during lactation and after weaning in osteocyte-specific sclerostin overexpressed mice.
    Lee SJ; Song SY; Rhee Y
    J Bone Miner Metab; 2020 Mar; 38(2):172-178. PubMed ID: 31501981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteocyte TSC1 promotes sclerostin secretion to restrain osteogenesis in mice.
    Liu W; Wang Z; Yang J; Wang Y; Li K; Huang B; Yan B; Wang T; Li M; Zou Z; Yang J; Xiao G; Cui ZK; Liu A; Bai X
    Open Biol; 2019 May; 9(5):180262. PubMed ID: 31088250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation.
    Bivi N; Condon KW; Allen MR; Farlow N; Passeri G; Brun LR; Rhee Y; Bellido T; Plotkin LI
    J Bone Miner Res; 2012 Feb; 27(2):374-89. PubMed ID: 22028311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes.
    Allison H; Holdsworth G; McNamara LM
    BMC Mol Cell Biol; 2020 Nov; 21(1):78. PubMed ID: 33148174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of sclerostin by the SIRT1 stabilization pathway in osteocytes.
    Kim JM; Yang YS; Xie J; Lee O; Kim J; Hong J; Boldyreff B; Filhol O; Chun H; Greenblatt MB; Gao G; Shim JH
    Cell Death Differ; 2022 Aug; 29(8):1625-1638. PubMed ID: 35169297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor α in osteocytes regulates trabecular bone formation in female mice.
    Kondoh S; Inoue K; Igarashi K; Sugizaki H; Shirode-Fukuda Y; Inoue E; Yu T; Takeuchi JK; Kanno J; Bonewald LF; Imai Y
    Bone; 2014 Mar; 60():68-77. PubMed ID: 24333171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.
    Atkins GJ; Rowe PS; Lim HP; Welldon KJ; Ormsby R; Wijenayaka AR; Zelenchuk L; Evdokiou A; Findlay DM
    J Bone Miner Res; 2011 Jul; 26(7):1425-36. PubMed ID: 21312267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and Sost in osteocytes at unloading.
    Moriishi T; Fukuyama R; Ito M; Miyazaki T; Maeno T; Kawai Y; Komori H; Komori T
    PLoS One; 2012; 7(6):e40143. PubMed ID: 22768243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes.
    Gooi JH; Pompolo S; Karsdal MA; Kulkarni NH; Kalajzic I; McAhren SH; Han B; Onyia JE; Ho PW; Gillespie MT; Walsh NC; Chia LY; Quinn JM; Martin TJ; Sims NA
    Bone; 2010 Jun; 46(6):1486-97. PubMed ID: 20188226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
    Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels.
    Chang MK; Kramer I; Huber T; Kinzel B; Guth-Gundel S; Leupin O; Kneissel M
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):E5187-95. PubMed ID: 25404300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive and Negative Regulators of Sclerostin Expression.
    Iwamoto R; Koide M; Udagawa N; Kobayashi Y
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.